Catalyst Calendar

Fri, Aug 14, 2026

1 updates

1:00 AM

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

NEW YORK & LYON, France, August 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin...

valneva.com

Thu, Aug 13, 2026

1 updates

VALN

1:00 AM

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering [1] Restructuring program implemented with positive P&L and cash flow impacts expected in the second...

valneva.com

Wed, Jul 22, 2026

1 updates

VALN

11:45 AM

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update....

valneva.com

Thu, Jun 25, 2026

1 updates

VALN

11:45 AM

Valneva Announces Successful Outcome of its Annual General Meeting

Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held earlier today in Lyon, France....

valneva.com